Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791880 | 0.81 | DRD3 (0.61) | ACHEHRH3DRD3KAT2BTDP1 | |
| SCHEMBL9132030 | 0.80 | ALDH1A1 (0.45) | ACHEHRH3ALDH1A1L3MBTL1TDP1 | |
| SCHEMBL4922627 | 0.79 | DRD3 (0.63) | ACHEHRH3DRD3KAT2BTDP1 | |
| SCHEMBL14426326 | 0.76 | CYP1A2 (0.61) | ACHEHRH3ALDH1A1DRD3L3MBTL1 | |
| SCHEMBL5840221 | 0.74 | MAPT (0.54) | ACHEALDH1A1GAAL3MBTL1POLB | |
| SCHEMBL23900804 | 0.74 | ACHE (0.52) | ACHEHRH3ALDH1A1DRD3KAT2B | |
| SCHEMBL14175271 | 0.74 | MAPT (0.55) | ACHEHRH3ALDH1A1GAAL3MBTL1 | |
| SCHEMBL14345460 | 0.73 | CYP1A2 (0.62) | ACHEHRH3ALDH1A1L3MBTL1 | |
| SCHEMBL10984454 | 0.73 | ACE2 (0.47) | ALDH1A1POLB | |
| SCHEMBL8673780 | 0.73 | POLB (0.59) | ACHEHRH3ALDH1A1DRD3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11603355-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3938345-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185830-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ACHE 305/4885HRH3 142/4885ALDH1A1 2736/4885 |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ACHE 305/4885HRH3 142/4885ALDH1A1 2736/4885 |
| US-11603355-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ACHE 305/4885HRH3 142/4885ALDH1A1 2736/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ACHE 305/4885HRH3 142/4885ALDH1A1 2736/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ACHE 305/4885HRH3 142/4885ALDH1A1 2736/4885 |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | ACHE 305/4885HRH3 142/4885ALDH1A1 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.